Open Question

How much of the published glioma imaging-AI literature survives rigorous external, multi-scanner, prospective validation — and what is the true generalization gap?

Evidence grade: STRONG — Supported by strong evidence.

Why it matters

Deployment and trust depend entirely on external performance; if most claims collapse on transfer, the field's evidentiary base is weaker than it appears. Note the STRONG evidence for this failure mode comes from adjacent medical-imaging AI; the glioma-specific meta-review has not been done.

Conflicting evidence

Internal AUCs are high; systematic reviews of medical-imaging AI (e.g. an emergency head-CT CNN meta-review [Menp2024]) find external validation rare and TRIPOD reporting adherence poor, and no equivalently rigorous glioma-imaging external-validation meta-review yet exists — the gap this question targets.

What would resolve it

Meta-research: systematic re-validation of top-cited models on held-out multi-institutional data with standardized reporting (CLAIM/TRIPOD-AI); publish the generalization-gap distribution.

Open in the interactive atlas →

About this page

Curated and maintained by Resonant Labs. Reviewed by Claims are synthesized from the cited literature and graded per the Atlas methodology (about the Atlas). Last updated 2026-07-01.

This is an educational research resource from Resonant Labs, not clinical advice. Evidence grades and controversies are summarized from the literature and may change as the field evolves.